Mirgorodsky D. Thrombolytic therapy of acute venous thrombosis (eхperimental-clinical research)

The work consists of experimental (EP) and clinical (CP) parts. EP: in the period from 2002 to 2006, 45 Chinchilla rabbits breed of both sexes weighing 3.2-4 kg, were simulated acute phlebothrombosis on femoral veins from further study of tissue reactions of morfothrombogenesis and implementation of thrombolytic therapy (TLT) aktylize (TAP) and the combination of the TAP + plasminogen (P) in the limit-possible therm. Experimental drugs effectiveness TLP TAP + P significantly higher than the TAP as the second and the third day of observation: the average value of thrombs area decreased respectively 2.5 and 1.5 on the second day and 1 and 0.5 times for the third day. CP: in the period from 2003 to 2010 years in the study included 95 patients with acute DVTLE. Men were 54, women - 41. Age of patients within the limits of 31 to 72 years, an average of 52±4.8 years. If DVTLE up to 7 days may be used as thrombolytic therapy, and the fact that ensure full recovery of blood flow in almost 50% of patients and partial restoration of blood flow over 35% of patients. TLT using TAP has several advantages over it. If there is indication of thrombosis than two weeks in the patients achieved positive haemodynamic (partial recanalization - 38.5%) and clinical effect (84.6%). TLT leads to complete clearance recanalization thrombose vessels in 36.59% patients, partial - in 48.78%, 14.63% in recanalization happens. The positive effect of timing of thrombolytic therapy in existence for more than two weeks DVTLE significantly associated with remitting type of disease course: r=0.423, p=0.045.